Cancer clinical trials in the region Pays de la Loire

413 currently recruiting clinical trials
Region Pays de la Loire

Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06824467 #2023-508015-23-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required FIGO stages
Stage III Stage IV
Required number of previous lines of therapy for current stage of disease
1 2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT06712355 #2024-515765-34-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy Bispecific T-cell engager antibodies
7 recruiting sites
BioNTech SE
Phase 3 Colon cancer Rectal cancer #NCT06107920 #2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
28 recruiting sites
Hôpital universitaire de Rouen
Phase 3 Breast cancer #NCT06435429
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Jazz Pharmaceuticals
Phase 3 Breast cancer #NCT06103864 #2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3 Breast cancer #NCT06103864 #2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
8 recruiting sites
AstraZeneca
Phase 3 Prostate cancer #NCT07213674 #2025-520555-89-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Amgen
Phase 3 Breast cancer #NCT06982521 #2025-523083-21-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None 1 2
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy Hormone therapy
Excluded genetic anomalies
AKT PTEN
Excluded previous treatments at localized stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
16 recruiting sites
Relay Therapeutics, Inc.
Phase 3 Endometrial cancer #NCT06340568 #2023-507525-42-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Immunotherapy Chemotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Chemotherapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
8 recruiting sites
BioNTech SE
Phase 3 Lymphoma #NCT06149286 #2022-503092-28-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma Marginal zone lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
16 recruiting sites
Regeneron Pharmaceuticals